Trade-Ideas: Cytokinetics (CYTK) Is Today's "Dead Cat Bounce" Stock
- CYTK has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $12.4 million.
- CYTK has traded 82,913 shares today.
- CYTK is up 3.8% today.
- CYTK was down 5.7% yesterday.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in CYTK with the Ticky from Trade-Ideas. See the FREE profile for CYTK NOW at Trade-Ideas More details on CYTK: Cytokinetics, Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Currently there are 4 analysts that rate Cytokinetics a buy, no analysts rate it a sell, and none rate it a hold. The average volume for Cytokinetics has been 568,100 shares per day over the past 30 days. Cytokinetics has a market cap of $290.7 million and is part of the health care sector and drugs industry. The stock has a beta of 0.66 and a short float of 10.5% with 1.94 days to cover. Shares are up 42.9% year-to-date as of the close of trading on Thursday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Cytokinetics as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and poor profit margins. Highlights from the ratings report include:
- The company's current return on equity has slightly decreased from the same quarter one year prior. This implies a minor weakness in the organization. Compared to other companies in the Biotechnology industry and the overall market, CYTOKINETICS INC's return on equity significantly trails that of both the industry average and the S&P 500.
- The gross profit margin for CYTOKINETICS INC is currently lower than what is desirable, coming in at 26.42%. Despite the low profit margin, it has increased significantly from the same period last year. Despite the mixed results of the gross profit margin, CYTK's net profit margin of 26.82% compares favorably to the industry average.
- CYTOKINETICS INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. However, we anticipate underperformance relative to this pattern in the coming year. During the past fiscal year, CYTOKINETICS INC continued to lose money by earning -$1.34 versus -$2.46 in the prior year. For the next year, the market is expecting a contraction of 3.7% in earnings (-$1.39 versus -$1.34).
- The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Biotechnology industry. The net income increased by 157.0% when compared to the same quarter one year prior, rising from -$11.46 million to $6.53 million.
- This stock has increased by 46.15% over the past year, outperforming the rise in the S&P 500 Index during the same period. Regarding the future course of this stock, we feel that the risks involved in investing in CYTK do not compensate for any future upside potential, despite the fact that it has seen nice gains over the past 12 months.
- You can view the full Cytokinetics Ratings Report.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Check Out Our Best Services for Investors
Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.